Biomarkers in Parkinsonian Syndromes

Conditions: Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Atypical Parkinsonism, Parkinsonism

Sex: All

Healthy volunteers: No

Enrollment: 200

Sponsor: Non-profit organization for scientific research in Parkinson's disease and related disorders

Location: HYGEIA Hospital, Parkinson's disease and Movement Disorders Department Athens Athens

Summary

This is a prospective observational study to identify biomarkers in parkinson syndromes. Patients with parkinsonian syndromes at the early stages of disease will be recruited and will be followed up until their established clinical diagnosis or for at least 5 years. In this population, imaging and wet biomarkers as well as clinical data will b systematically collected.

Eligibility Criteria

IΙnclusion Criteria: * Written informed consent, including consent to monitoring * Patients with Parkinsonism and disease duration \< 2 years * Patients with Parkinsonism and disease duration \> 2 years * Healthy individuals without any neurological disease Exclusion Criteria: * Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide). * Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism). * Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm * Other serious diseases that indicate a life expectancy of \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06501469). StuddyBuddy aggregates publicly available trial information.